title: Improving the cardio protective effect of aFGF in ischemic myocardium with ultrasound-mediated cavitation of heparin modified microbubbles: preliminary experiment.
abstract: Ultrasound (US)-mediated cavitation of microbubbles has evolved into a new tool for organ-specific gene and drug delivery. This paper was to investigate the feasibility of acidic fibroblast growth factor (aFGF) intravenous delivery to the ischemic myocardium of rats by ultrasonic microbubbles modified with heparin. Heparin modified microbubbles (HMB) were prepared by the freeze-dried method. Acute myocardial infarction (AMI) model was established and the cardio protective effect of the aFGF combing with HMB (aFGF-HMB) under US-mediated cavitation technique was investigated. aFGF-HMB combined with US-mediated cavitation technique was examined by ECG. Ejection fraction (EF), fractional shortening (FS) and left ventricular diastolic diameter (LVDd) were measured to monitor the improvement of global myocardial contractile function. Myocardial tissue was stained with hematoxylin and eosine (HE) to evaluate the elaborate general morphology of the ischemic myocardium. From morphologic observation and echocardiography in rat heart, aFGF-HMB had suitable size distribution, physical stability and good acoustic resonance function. From AMI rat experiments, aFGF-HMB under US-mediated cavitation technique exerted aFGF cardio protective effect in ischemic myocardium. From histological evaluation, US-mediated cavitation of aFGF-HMB showed improvement of myocardial ischemia. With the visual imaging and US-triggered drug release advantages, US-mediated cavitation of aFGF-HMB might be developed as a novel technique for targeting delivery of aFGF into ischemic myocardium.
authors: Wenzhou Medical College, Wenzhou City, Zhejiang Province, China.
authors: Ying-Zheng
authors: YZ
authors: Zhao
authors: Cui-Tao
authors: CT
authors: Lu
authors: Xiao-Kun
authors: XK
authors: Li
authors: Qin-Qin
authors: QQ
authors: Tang
authors: Xin-Qiao
authors: XQ
authors: Tian
authors: Ya-Ping
authors: YP
authors: Zhao
authors: Yan
authors: Y
authors: Zhang
authors: Ji-Lai
authors: JL
authors: Tian
authors: Wei
authors: W
authors: Yang
authors: Shuping
authors: S
authors: Ge
authors: Chandra K
authors: CK
authors: Nair
authors: Xuedong
authors: X
authors: Shen
mesh_terms: D000818:Animals; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003287:Contrast Media / Q000008:administration & dosage* / Q000627:therapeutic use; D004195:Disease Models, Animal; D004337:Drug Carriers / Q000008:administration & dosage / Q000627:therapeutic use; D016503:Drug Delivery Systems / Q000379:methods; D004452:Echocardiography / Q000379:methods; D016220:Fibroblast Growth Factor 1 / Q000008:administration & dosage* / Q000627:therapeutic use*; D006493:Heparin / Q000008:administration & dosage* / Q000627:therapeutic use; D007275:Injections, Intravenous; D008297:Male; D045423:Microbubbles / Q000627:therapeutic use*; D009200:Myocardial Contraction / Q000187:drug effects / Q000502:physiology; D017202:Myocardial Ischemia / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013016:Sound
chemical_list: D002316:Cardiotonic Agents; D003287:Contrast Media; D004337:Drug Carriers; D016220:Fibroblast Growth Factor 1; D006493:Heparin